What is AMPLY Discovery?
Founded in 2021, AMPLY Discovery operates at the intersection of computational biology and pharmaceutical development. By leveraging advanced artificial intelligence to mine complex digital biological datasets, the company identifies alternative natural compounds with potent anti-infective properties. This approach significantly reduces the time and cost associated with traditional drug discovery pipelines, offering a scalable solution for both human and animal health challenges. The company's market position is bolstered by its strategic location in the United Kingdom, allowing it to tap into a robust ecosystem of research institutions and government-backed innovation initiatives.
How much funding has AMPLY Discovery raised?
AMPLY Discovery has raised a total of $3.8M across 3 funding rounds:
Unspecified
$1M
Grant
$1M
Seed
$1.8M
Unspecified (2022): $1M with participation from Co-fund NI, QUBIS Innovation Fund, and Helix Way Partnership
Grant (2024): $1M led by Innosuisse and UK Research & Innovation
Seed (2025): $1.8M supported by British Business Bank, Venture Science, and Twin Path Ventures
Key Investors in AMPLY Discovery
Venture Science
Venture Science specializes in AI-driven quantitative investing, focusing on high-impact technology investments through data-informed strategies.
Twin Path Ventures
Twin Path Ventures is an investment firm that specializes in backing AI-first startups from their inception, providing early-stage funding and strategic guidance.
British Business Bank
British Business Finance is a subsidiary of the British Business Bank, focused on increasing the supply of credit to small and medium enterprises to foster economic growth.
What's next for AMPLY Discovery?
With the infusion of this latest capital, AMPLY Discovery is expected to scale its computational infrastructure and expand its laboratory operations. The strategic focus will likely shift toward validating lead candidates identified through its AI platform and initiating pre-clinical trials. By maintaining a disciplined approach to research and development, the company aims to solidify its role as a key player in the next generation of biopharmaceutical innovation. Future milestones will likely involve strategic partnerships with larger pharmaceutical entities to accelerate the path to market for its anti-infective portfolio.
See full AMPLY Discovery company page
